Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence

Figures & data

Table 1 Antimicrobials in Phase III Clinical Trials

Drug Name	Drug Class	Development Phase	Study Results *	Data Approval by FDA
Omadacycline	Aminomethylcycline (derivate of tetracyclines)	Phase III	Clinical response: 81.1% (313/386) vs 82.7% (321/388) comparator.	10/02/2018
Delafloxacin	Fluoroquinolone	Phase III	Clinical response: 90.5% (390/431) vs 89.7% (384/428) comparator	10/24/2019
Lefamulin	Pleuromutilin	Phase III	Clinical response: 89.3% (577/646) vs 90.2% (582/645) comparator	8/19/2019
Solithromycin	Macrolide	Phase III	Clinical response: 78.7% (677/860) vs 78.8% (680/863) comparator	Not yet approved
Nemonoxacin	Non-fluorinated quinolone	Phase III	Clinical cure: 89.1% (542/608) vs 88.5% (261/295)	Not yet approved

Note: * Expressed in percentage and number.

Table 2 Compounds in Phase I and II Clinical Trials

Drug name	Drug Class	Development Phase	Study Results *	NCT	Reference
Zabofloxacin	Fluoroquinolone	Phase II	No results available	NCT00640926
Aravofloxacin	Fluoroquinolone	Phase II	Clinical cure: 87.5% (14/16) vs 81.3% (13/16) comparator	NCT01198626	^Citation57
Nafithromycin	Ketolide	Phase II	Clinical response: 91.9% (68/74) vs 87% (67/77) comparator	NCT02903836	^Citation61
TP-271	Tetracycline	Phase I	No results available	NCT02724085
Gepotidacin	Tetracycline	Phase I	No results of efficacy available	NCT02853435	^Citation64
Radezolid	Oxazolidinone	Phase II	Clinical cure: 78% (103/132)	NCT00640926	^Citation66
Delpazolid	Oxazolidinone	Phase I	No results of efficacy available	NCT01842516	^Citation68
CAL02	Antitoxin agent	Phase II	Clinical cure: 100% (12/12) vs 100% (5/5) comparator	NCT02583373	^Citation70

Note: * Expressed in percentage and number.

Covington PS, Davenport JM, Andrae DA, et al. A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia. J Antimicrob Chemother. 2013;68:2691–2693. doi:10.1093/jac/dkt217

 PubMed Web of Science ®Google Scholar

Phase II study of oral nafithromycin in CABP - Study results - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02903836. Accessed Jul 7, 2020.

 Google Scholar

Tiffany CA, Hossain M, McDonald M, et al. Safety and pharmacokinetics of single escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor. Abstr 53rd Intersci Conf Antimicrob Agents Chemother. 2013;abstr F–1218.

 Google Scholar

Safety and efficacy study of oxazolidinone to treat pneumonia. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00640926?cond=radezolid&draw=2&rank=1. Accessed Jul 7, 2020.

 Google Scholar

Multiple ascending dose study for LCB01–0371. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01842516. Accessed Jul 7, 2020.

 Google Scholar

Laterre PF, Colin G, Dequin PF, et al. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2019;19:620–630. doi:10.1016/S1473-3099(18)30805-3

 PubMed Web of Science ®Google Scholar